🇺🇸 FDA
Pipeline program

therapeutic autologous dendritic cells

CDR0000068481

Phase 2 mab completed

Quick answer

therapeutic autologous dendritic cells for Melanoma (Skin) is a Phase 2 program (mab) at LISATA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
LISATA THERAPEUTICS, INC.
Indication
Melanoma (Skin)
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials